SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-23-019610
Filing Date
2023-07-07
Accepted
2023-07-07 16:30:45
Documents
13
Period of Report
2023-07-07
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K vtgn20230706_8k.htm   iXBRL 8-K 25128
  Complete submission text file 0001437749-23-019610.txt   156035

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA vtgn-20230707.xsd EX-101.SCH 3408
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE vtgn-20230707_def.xml EX-101.DEF 11423
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vtgn-20230707_lab.xml EX-101.LAB 15309
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vtgn-20230707_pre.xml EX-101.PRE 11583
7 EXTRACTED XBRL INSTANCE DOCUMENT vtgn20230706_8k_htm.xml XML 2563
Mailing Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 343 ALLERTON AVENUE SOUTH SAN FRANCISCO CA 94080 650-577-3600
Vistagen Therapeutics, Inc. (Filer) CIK: 0001411685 (see all company filings)

IRS No.: 205093315 | State of Incorp.: NV | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-37761 | Film No.: 231077132
SIC: 2834 Pharmaceutical Preparations